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Changes of apoptosis-related molecules on ERK signaling pathway in KBD patients 
suggested that ERK signaling pathway might play important roles in molecular biol-
ogy mechanism of KBD, and Na2SeO3 could promote activation of pRaf-1，pMek1/2 
and pErk1/2. *This research is supported by National Natural Science Foundation 
(No. 30671820，81172610).
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Objectives: Flail chest occurs in 6-15% of patients sustaining blunt chest wall 
trauma and can be life-threatening. It is typically managed through supportive 
therapies (e.g. ventilation, pain control) but an increasing body of evidence shows 
decreased patient mortality and morbidity with rib fixation surgery. The objective 
of our study was to evaluate the budget impact of changing the treatment for flail 
chest from supportive therapy to surgical management with contoured titanium 
plates in a Canadian hospital. MethOds: A budget impact model was created using 
clinical and economic data obtained from peer-reviewed literature, the Ontario 
Case Costing Initiative and case costing data from a large Canadian hospital. A 
2013 meta-analysis was used to provide efficacy data on the reduction of health 
care resources associated with surgical management. The outcomes are reflective 
of a hospital that treats 10 patients with flail chest per year. The model takes into 
consideration costs associated with surgery, length of stay and the common com-
plications associated with flail chest. A multivariate sensitivity analysis utilizing 
a Monte Carlo simulation was conducted on economic and clinical parameters to 
ensure robustness. Results: The model found that shifting the treatment of flail 
chest from supportive to surgical management decreased the number of ventilation 
days from 13.9 to 6.4 and the total hospital stay from 27.2 to 18.4 days. It also found 
a reduction in the incidence of complications such as tracheostomies from 78.94% 
to 18% and pneumonia from 89.47% to 62%. Accounting for the additional costs 
associated with fixation devices and surgical management, the model establishes 
that surgical rib fixation for flail chest has the potential to provide a Canadian hos-
pital with an annual net cost savings of CAD$214,660. cOnclusiOns: Shifting the 
treatment of flail chest from supportive to surgical management with contoured 
titanium plates is a cost-effective solution for Canadian hospitals.
PMs15
BuDget iMPact analysis of aPixaBan versus enoxaParin in Patients 
unDergoing total hiP or knee rePlaceMent in coloMBia
Ordoñez Molina J.E.1, Garrido Lecca S.2, Vargas Zea N.3, Prieto Martinez V.4
1HEMOGROUP Hematoncology Medical Center, Medellín, Colombia, 2Bristol-Myers Squibb 
Company, Lima, Peru, 3Pfizer S.A.S., Bogotá, Colombia, 4Pfizer S.A.S., Bogota, Colombia
Objectives: The aim of this analysis is to estimate the budget impact of apixaban 
compared with enoxaparin in patients undergoing total knee replacement (TKR) or 
total hip replacement (THR) in Colombia. MethOds: A model was built with a time 
horizon of five years. The comparators were: apixaban (2.5 mg BID) and enoxaparin 
(40 mg OD). The number of expected cases was calculated from the population 
census (2011) considering a growth rate of 1.2 % and an annual frequency of 0.015 
% for TKR and 0.016 % for THR, which were taken from a health insurance company 
in Colombia with over 1,800,000 affiliates nationwide. The duration of treatment for 
patients undergoing TKR (12 days) or THR (35 days) and safety data were taken from 
the literature. The analysis used the third payer perspective including direct medical 
costs and expressed in 2013 $US. The costs were taken from SISMED for drugs and 
SOAT tariff for medical procedures. Discount rate of 3 % was applied. The market 
share was estimated based on SISMED and the projected demand validated by 
expert’s opinions. Results: In a period of five years, if apixaban gets an 18 % of the 
market that currently has enoxaparin, the decrease in over total annual costs would 
be 8.8 % ($ US 5,052,857). The reduction in costs is due to fewer complications (VTE, 
pulmonary embolism and bleeding) in patients who were administered apixaban 
and a lower treatment day cost compared with enoxaparin. cOnclusiOns: The 
inclusion of apixaban in the health care reimbursement list, as thromboprophylactic 
treatment for patients undergoing TKR or THR, decreases total costs of care for the 
health system in Colombia.
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Objectives: To estimate the economic impact for Colombian health budget by 
including frontline tocilizumab used as monotherapy or in combination with 
methotrexate in patients with RA refractory to treatment with non-biologic 
DMARDs. MethOds: The population over 18 years reported by DANE, for the period 
2013-2017 was used as population risk of developing RA. This was discriminated 
by age, sex and type of affiliation. The target population were considered patients 
over 18 years with RA refractory to treatment with non-biologic DMARDs. We used 
a prevalence of 0.5% and a range for sensitivity analysis of 0.25% and 1%; the per-
centage of patients with RA using biological (4.7%) corresponded to that reported 
by literature. Intervention evaluated was: tocilizumab 8mg/Kg each 4 weeks and 
tocilizumab 8mg/Kg each 4 weeks +metotrexate 15 mg/week. Actual technology: 
adalimumab 40 mg/ sc/biweekly +metotrexate 15 mg/week; adalimumab 40 mg/ 
sc/biweekly; etanercept 50 mg/sc/week +metotrexate 15 mg/week; etanercept 
50 mg/ sc/week; infliximab 3 mg/kg IV induction regimen at 0, 2 and 6 weeks 
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Objectives: To describe baseline characteristics of elderly patients with 
Rheumatoid Arthritis (RA) initiating therapy with Certolizumab Pegol ( CZP) and 
other TNF-a inhibitors (TNFi). MethOds: Cross-sectional analysis of RA patients 
older than 65 years of age, initiating CZP or another TNFi following enrollment 
in the CORRONA registry. Baseline demographic and clinical characteristics of 
included patients were assessed. Each characteristic was compared between CZP 
and other TNFi initiators using either Student’s two-sample t-test or the chi-square 
test. Results: 1062 initiations of TNFi in RA patients older than 65 years were 
analyzed; 136 (12.8%) patients initiated CZP and 926 (87.2%) another TNFi. Baseline 
characteristics for CZP initiators (versus other TNFi): age (mean±Standard devia-
tion (SD)) 72.2±6.4 (vs. 72.1±6.3, p> 0.05), female 72.8% (vs. 74.6%, p> 0.05), disease 
duration 12.1±9.9 (vs. 13.5±11.3, p> 0.05), baseline CDAI 23.8±14.4 (vs. 18.0±12.9, p: 
< 0.001), baseline mHAQ 0.50±0.51 (vs. 0.46±0.50, p> 0.05). At the time of CZP initia-
tion 45.9% of patients had high disease activity and 39.8% had moderate disease 
activity by CDAI (vs 32.8% and 33.7 respectively for other TNFi initiators, p: < 0.0001). 
Concomitant methotrexate use was present in 49.3% of CZP initiators (vs 63.3 for 
other TNFi, p 0.002). In 40.4% of CZP initiators, CZP was used after failure of two or 
more prior biologics (vs 30.2% in other TNFi initiators, p: 0.026). cOnclusiOns: 
The present descriptive analyses suggest that elderly CZP initiators have similar 
demographic characteristics with initiators of other TNFi. However, CZP is used 
more frequently after prior failure to 2 or more TNFi, is more commonly given as 
monotherapy, and initiated in patients with a higher mean disease activity com-
pared to other TNFi.
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Objectives: The prevalence of juvenile idiopathic arthritis (JIA) is approximately 
3.3/1000 children and 10-15% have the systemic form (SJIA). Biologics, specifically 
anti-IL1 and anti-IL6 therapy have dramatically reduced the prolonged use of cor-
ticosteroids and therefore decreased the associated morbidity including growth 
failure, cataracts, fractures and body image problems. This study aims to determine 
the prevalence of SJIA and biologic use in SJIA in Ontario. MethOds: All patients 
seen at the Rheumatology Clinic of the Hospital for Sick Children (SickKids), Toronto 
with a diagnosis of SJIA from December 1986 to January 2013 were eligible. Exclusion 
criteria: Diagnosis not confirmed, < 1 year follow-up, < 1 visit per year and unable 
to obtain complete medical record. Data for Ontario SJIA prevalence was estimated 
through personal communication with all practicing pediatric rheumatologists in 
Ontario. Results: The cohort consisted of 268 SJIA patients which represented 
13% of the total JIA cohort. Since 2012, when anti-IL-1 and anti-IL-6 medications 
were readily available in Ontario, 12/23 (52%) of newly diagnosed patients received 
either anti-IL-1 or anti-IL-6 (11/12 received anti-IL-1 therapy). In the other 3 pediatric 
rheumatology centres in Ontario, 9 additional SJIA patients were diagnosed and 3 
received anti-IL-1 and 2 anti-IL-6. Medication choice was based on the patient’s 
drug coverage, patient/parent preference for intravenous vs. subcutaneous mode 
of administration and distance from an infusion centre. No other biologic (anti-TNF 
for example) was started in any of these patients. cOnclusiOns: In Ontario there 
are approximately 150 patients with SJIA followed by pediatric rheumatologists. 
Although this group constitutes a small proportion of the total JIA population, they 
require more intensive therapy with 50% treated with a biologic as compared to 
10-15% of total all JIA patients currently followed at SickKids.
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Objectives: Kashin-Beck disease (KBD) is an endemic, deformable, and chronic 
osteoarthropathy prevailing in selenium (Se)-deficiency regions, while its etiopatho-
genesis maintains obscure. Type 2 Deiodinase (DIO2) is an important Se-dependent 
antioxidant enzyme and there are many polymorphisms in DIO2 gene, among 
which, Thr92Ala，rs225014，has been studied widespread in diseases. In many dif-
ferent cells, ERK signalling pathway palys a role in anti-apoptosis and decreased ERK 
activity is necessary for apoptosis. Therefore, we investigated possible association 
between DIO2 Thr92Ala and susceptibility to KBD in a Chinese population.To explore 
molecular mechanism of cartilage apoptosis and role of Se in prevention in KBD, 
expression of signal molecules of ERK pathway in controls and KBD patients are 
detected and Na2SeO3 are added to explore it’s effect on ERK pathway. MethOds: 
218 KBD patients and 209 age and sex matched controls were enrolled and served 
as KBD and control group respectively. Polymerase Chain Reaction-Restriction 
Fragment Length Polymophism (PCR-RFLP) is used to analyze DIO2 Thr92Ala poly-
morphism. Real-Time PCR is used to detect DIO2 mRNA. Western-blot is used to 
detect expression of signal molecules of ERK transduction pathway. Results: 
No difference were found in genotypic and allelic frequency of DIO2 Thr92Ala 
between KBD and control group (P> 0.05). DIO2 mRNA level of cartilage tissue was 
significantly different between KBD and controls (P< 0.05). Expression of pRaf-1, 
pMek1/2 and pErk1/2 decreased significantly in KBD patients (0.72~, 0.78~ and 0.28 
fold respectively, P< 0.05) compared with controls. cOnclusiOns: no association 
was found between DIO2 Thr92Ala polymorphism and KBD incidence. Expression 
of DIO2 mRNA in KBD patients decreased significantly coampared with controls. 
